BioCryst Pharmaceuticals (NASDAQ:BCRX) outlined a multi-pronged growth strategy at the JPMorgan Healthcare Conference, ...
Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE ...
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to ...
Pharming Group ( (PHAR) ) has issued an announcement.
Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. The stock rose 14%, to $17.99, in ...
Stocktwits on MSN
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart
KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and ...
Investing.com -- KalVista Pharmaceuticals Inc (NASDAQ:KALV) stock surged 16.9% in after-hours trading Thursday following the ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, ...
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44 th Annual J.P. Morgan ...
Patients with hereditary angioedema using deucrictibant as an on-demand treatment for attacks achieved onset of symptom ...
As described in Overview, the impact of hereditary angioedema (HAE) on psychosocial health and quality of life (QoL) is substantial, with patients frequently reporting anxiety, depressive symptoms, ...
The European Medicines Authority’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for a new drug to treat hereditary angioedema (HAE).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback